<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256411</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2219E1</org_study_id>
    <nct_id>NCT01256411</nct_id>
  </id_info>
  <brief_title>A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension</brief_title>
  <official_title>An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long-term safety, tolerability and efficacy of
      LCZ696.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Participants were monitored throughout the study for adverse events, serious adverse events and deaths.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Maximum Treatment)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Mono or Combination Therapy)</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Pressure Control Rate of &lt;140/90 mmHg (Analysis by Maximum Treatment)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Blood pressure (BP) control is defined as BP &lt;140/90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Pressure Control Rate of &lt;140/90 mmHg (Analysis by Mono or Combination Therapy)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Blood pressure (BP) control is defined as BP &lt;140/90 mmHg.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">341</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide (HCTZ)</intervention_name>
    <description>Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have successfully completed protocol No. CLCZ696A2219 and who, as judged
             by the study investigator, are able to continue in the current study.

          -  Ability to communicate and comply with all study requirements and demonstrate good
             medication compliance during CLCZ696A2219.

        Exclusion Criteria:

          -  Patients who did not complete CLCZ696A2219.

          -  Presence of significant protocol violation in CLCZ696A2219.

          -  Patients who are deemed to be unable to comply with the protocol by the investigator.

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>100-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kunitachi</city>
        <state>Tokyo</state>
        <zip>186-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>424-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koyang</city>
        <state>Kyunggi</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <results_first_submitted>July 21, 2015</results_first_submitted>
  <results_first_submitted_qc>September 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>blood pressure</keyword>
  <keyword>LCZ696</keyword>
  <keyword>dual-acting</keyword>
  <keyword>neprilysin</keyword>
  <keyword>nep inhibitor</keyword>
  <keyword>vasopeptidase</keyword>
  <keyword>angiotensin receptor</keyword>
  <keyword>angiotensin receptor neprilysin inhibitor (ARNi)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Analyses on this open label extension study were performed according to treatment groups defined by the maximum and highest dose treatments received: 1) LCZ696 200 mg, 2) LCZ696 400 mg, 3) LCZ696 400 mg/Amlodipine, 4) LCZ696 400 mg/Amlodipine/HCTZ, 5) LCZ696 Mono (LCZ696 only), and 6) LCZ696 Combination LCZ696 with Amlodipine and/or HCTZ).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 200 mg</title>
          <description>Participants received LCZ696 200 mg by mouth once daily (qd).</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 400 mg</title>
          <description>Participants received LCZ696 400 mg by mouth qd.</description>
        </group>
        <group group_id="P3">
          <title>LCZ606 400 mg/Amlodipine</title>
          <description>Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn).</description>
        </group>
        <group group_id="P4">
          <title>LCZ696 400 mg/Amlodipine/HCTZ</title>
          <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
        </group>
        <group group_id="P5">
          <title>LCZ696 Monotherapy</title>
          <description>Participants received LCZ696 only.</description>
        </group>
        <group group_id="P6">
          <title>LCZ696 Combination Therapy</title>
          <description>Participants received LCZ696 with amlodipine and/or HCTZ.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Extension by Maximum Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Down Titrated to 100 mg</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension by Mono or Combination Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="228"/>
                <participants group_id="P6" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="211"/>
                <participants group_id="P6" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 200 mg</title>
          <description>Participants received LCZ696 200 mg by mouth once daily (qd).</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 400 mg</title>
          <description>Participants received LCZ696 400 mg by mouth qd.</description>
        </group>
        <group group_id="B3">
          <title>LCZ606 400 mg/Amlodipine</title>
          <description>Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn).</description>
        </group>
        <group group_id="B4">
          <title>LCZ696 400 mg/Amlodipine/HCTZ</title>
          <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="341"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="9.69"/>
                    <measurement group_id="B2" value="50.3" spread="10.14"/>
                    <measurement group_id="B3" value="52.5" spread="9.53"/>
                    <measurement group_id="B4" value="46.3" spread="2.06"/>
                    <measurement group_id="B5" value="51.8" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment)</title>
        <description>Participants were monitored throughout the study for adverse events, serious adverse events and deaths.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Actual extension treatment received: The participants are included in each treatment group for which they received treatment. For example, if a participant started on LCZ696 200 mg but was then down-titrated to LCZ696 100 mg, the participant was counted once in the LCZ696 100 mg group and once in the LCZ696 200 mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg by mouth once daily (qd).</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg by mouth qd.</description>
          </group>
          <group group_id="O3">
            <title>LCZ606 400 mg/Amlodipine</title>
            <description>Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn).</description>
          </group>
          <group group_id="O4">
            <title>LCZ696 400 mg/Amlodipine/HCTZ</title>
            <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
          </group>
          <group group_id="O5">
            <title>LCZ696 100 mg</title>
            <description>Participants were down-titrated to 100 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events, Serious Adverse Events, and Deaths (Analysis by Actual Treatment)</title>
          <description>Participants were monitored throughout the study for adverse events, serious adverse events and deaths.</description>
          <population>Actual extension treatment received: The participants are included in each treatment group for which they received treatment. For example, if a participant started on LCZ696 200 mg but was then down-titrated to LCZ696 100 mg, the participant was counted once in the LCZ696 100 mg group and once in the LCZ696 200 mg group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="112"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (serious and non-serious)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroius adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Maximum Treatment)</title>
        <description>Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 400 mg/Amlodopine group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg by mouth once daily (qd).</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg by mouth qd.</description>
          </group>
          <group group_id="O3">
            <title>LCZ606 400 mg/Amlodipine</title>
            <description>Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn).</description>
          </group>
          <group group_id="O4">
            <title>LCZ696 400 mg/Amlodipine/HCTZ</title>
            <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Maximum Treatment)</title>
          <description>Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.</description>
          <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 400 mg/Amlodopine group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>msDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="7.63"/>
                    <measurement group_id="O2" value="-14.2" spread="7.05"/>
                    <measurement group_id="O3" value="-17.4" spread="7.71"/>
                    <measurement group_id="O4" value="-16.8" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>msSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" spread="12.16"/>
                    <measurement group_id="O2" value="-21.3" spread="11.46"/>
                    <measurement group_id="O3" value="-28.1" spread="13.43"/>
                    <measurement group_id="O4" value="-29.0" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Mono or Combination Therapy)</title>
        <description>Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 combination group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Monotherapy</title>
            <description>Participants received LCZ696 only.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Combination Therapy</title>
            <description>Participants received LCZ696 with amlodipine and/or HCTZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) (Analysis by Mono or Combination Therapy)</title>
          <description>Sitting BP measurements were performed at every study visit. A negative change from baseline indicates improvement.</description>
          <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 combination group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>msDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="7.49"/>
                    <measurement group_id="O2" value="-17.3" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>msSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.0" spread="11.95"/>
                    <measurement group_id="O2" value="-28.2" spread="13.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Pressure Control Rate of &lt;140/90 mmHg (Analysis by Maximum Treatment)</title>
        <description>Blood pressure (BP) control is defined as BP &lt;140/90 mmHg.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 400 mg/Amlodopine group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 200 mg</title>
            <description>Participants received LCZ696 200 mg by mouth once daily (qd).</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 400 mg</title>
            <description>Participants received LCZ696 400 mg by mouth qd.</description>
          </group>
          <group group_id="O3">
            <title>LCZ606 400 mg/Amlodipine</title>
            <description>Participants received LCZ696 400 mg by mouth qd and amlodipine 5mg up to 10 mg by mouth as needed (prn).</description>
          </group>
          <group group_id="O4">
            <title>LCZ696 400 mg/Amlodipine/HCTZ</title>
            <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Pressure Control Rate of &lt;140/90 mmHg (Analysis by Maximum Treatment)</title>
          <description>Blood pressure (BP) control is defined as BP &lt;140/90 mmHg.</description>
          <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 400 mg/Amlodopine group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Pressure Control Rate of &lt;140/90 mmHg (Analysis by Mono or Combination Therapy)</title>
        <description>Blood pressure (BP) control is defined as BP &lt;140/90 mmHg.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 combination group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 Monotherapy</title>
            <description>Participants received LCZ696 only.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 Combination Therapy</title>
            <description>Participants received LCZ696 with amlodipine and/or HCTZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Pressure Control Rate of &lt;140/90 mmHg (Analysis by Mono or Combination Therapy)</title>
          <description>Blood pressure (BP) control is defined as BP &lt;140/90 mmHg.</description>
          <population>Treated set: The treated set included all participants who received at least one dose of extension study medication. One participant in the LCZ696 combination group discontinued after 1 day in the extension study without having any BP measurements taken during the extension. Therefore, this participant was excluded from the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 100 mg</title>
          <description>Participants were down-titrated to 100 mg.</description>
        </group>
        <group group_id="E2">
          <title>LCZ696 200 mg</title>
          <description>Participants received LCZ696 200 mg by mouth once daily (qd).</description>
        </group>
        <group group_id="E3">
          <title>LCZ696 400 mg</title>
          <description>Participants received LCZ696 400 mg by mouth qd.</description>
        </group>
        <group group_id="E4">
          <title>LCZ696 400 mg/Aml</title>
          <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
        </group>
        <group group_id="E5">
          <title>LCZ696 400 mg/Aml/HCTZ</title>
          <description>Participants received LCZ696 400 mg by mouth qd, amlodipine 5 mg up to 10 mg by mouth prn and HCTZ 6.25 mg and up to 25 mg by mouth prn.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Radicular cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="340"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

